Product Description
The global cerebral embolic protection device market was valued at $132.6 million in 2025. This is expected to increase over the forecast period at a CAGR of 11.2% to reach $279.3 million.
The full report suite on the global market for cerebral embolic protection device (CEPD) includes filters designed to capture or deflect emboli traveling to the brain during transcatheter aortic valve implantation procedures in order to protect the supra-aortic vessels from embolic debris.
The report includes data for 65 countries across 7 different regions which include North America, Latin America, Western Europe, Central & Eastern Europe, Middle East, Asia-Pacific, and Africa.
Data Types Included
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- Procedure Numbers
- Market Drivers & Limiters
- Market Forecasts Until 2032, and Historical Data to 2022
- Recent Mergers & Acquisitions
- Company Profiles and Product Portfolios
- Leading Competitors
Cerebral Embolic Protection Device Market Trends
The cerebral embolic protection device market remains closely tied to growth in structural heart procedures, particularly transcatheter aortic valve replacement (TAVR). Although clinical evidence on routine CEPD use has produced mixed results, expanding TAVR volumes and broader patient indications continue to support the addressable market. As TAVR moves into lower-risk populations, demand for cerebral embolic protection is increasingly driven by selective use in higher-risk cases, reflecting a shift from universal adoption toward determining when and where embolic protection is clinically and economically justified.
Cerebral Embolic Protection Device Market Share Insights
- Boston Scientific was the leading competitor in the global cerebral protection device market in 2025. The company offers the Sentinel™ cerebral protection product. The Sentinel™ is a dual-filter embolic protection device for use during TAVR. The company’s device remains the most popular global device, which will allow it to maintain the vast majority of market share over the next few years.
- Venus MedTech is the second-leading competitor in the global cerebral embolic protection device (CEPD) market. The company entered the market through its acquisition of Keystone Heart, the original developer of the TriGUARD 3™ cerebral embolic protection device, which is designed to deflect embolic debris and provide coverage of all three major cerebral vessels during transcatheter aortic valve replacement procedures. The TriGUARD 3™ has received regulatory approval in select regions, including Europe, and has seen initial clinical adoption in those markets. Venus MedTech has established regional popularity, particularly outside North America, and is expected to gain further regulatory approvals and expand adoption over the next few years as clinical experience and supporting evidence continue to grow.
Cerebral Embolic Protection Device Market Segmentation Summary
Cerebral Embolic Protection Market
Research Scope Summary
| Report Attribute | Details |
|---|---|
| Regions | North America (Canada, United States) Latin America (Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Guatemala, Mexico, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela) Western Europe (Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, United Kingdom) Central & Eastern Europe (Azerbaijan, Baltic States, Belarus, Bulgaria, Croatia, Czech Republic, Georgia, Greece, Hungary, Kazakhstan, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Turkey, Ukraine) Middle East (Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates) Asia Pacific (Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Kyrgyzstan, Macao, Malaysia, Mongolia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, Uzbekistan, Vietnam) Africa (Algeria, Egypt, Ethiopia, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda) |
| Base Year | 2025 |
| Forecast | 2026-2032 |
| Historical Data | 2022-2024 |
| Quantitative Coverage | Procedure Numbers, Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices. |
| Qualitative Coverage | Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease Overviews. |
| Data Sources | Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data, iData Research Internal Database. |
CONTACT US FOR ADDITIONAL INFORMATION
For full segmentation and any questions regarding research coverage, please contact us for a complimentary demo of the full report.
